Philadelphia chromosome-positive chronic myelogenous leukemia in treated Hodgkin's disease.
A patient who developed Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) 8 years after successful treatment for Hodgkin's disease (HD) is reported. The Ph chromosome with a typical 9(22) translocation was identified by banding techniques in 80% of bone marrow (BM) cells. Southern blot analysis showed breakpoint cluster region (BCR) rearrangement as observed in classical CML. Until now, only three cases of Ph + CML have been reported after treatment for HD. At present, it is not clear whether development of CML after HD represents a therapy-induced complication, an increased susceptibility to secondary malignancies owing to the malignant process itself, a consequence of the immunological deficiencies in HD, or possibly a genetic susceptibility to malignancy.
Verhoef
G E
GE
Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
Demuynck
H
H
Stul
M S
MS
Cassiman
J J
JJ
Mecucci
C
C
Van Den Berghe
H
H
Boogaerts
M A
MA
D015139:Blotting, Southern; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D004247:DNA / Q000032:analysis; D006689:Hodgkin Disease / Q000150:complications*; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D014178:Translocation, Genetic
D004247:DNA